As­traZeneca CEO Pas­cal So­ri­ot called on Eu­rope to step up in­vest­ments and “pro­tect its health sov­er­eign­ty” as it ...

Representatives from large vaccine makers say they are committed to their pipelines, despite a new wave of scrutiny in the US ...

Pfizer, Novartis, Amgen, Eli Lilly and J&J lead pharma lobbying spend amid policy changes. Issues include 340B program, drug ...

Fresh off a splashy obesity deal, Zealand Pharma is doubling down on its R&D ambitions with a new chief scientific officer.

Repertoire Immune Medicines makes a major announcement in April. And this year is no different. The Flagship ...

A small Northwestern University spinout attempting to develop a twist on biologics has pulled together a $30 million Series A ...

Summit Therapeutics and Akeso said their PD-1xVEGF bispecific antibody ivonescimab beat BeiGene’s PD-1 blocker Tevimbra in a ...

Eli Lilly on Thursday filed lawsuits against four telehealth companies over their sale of compounded versions of the GLP-1 ...

Ascletis Pharma's obesity drug ASC30 shows puzzling results in Phase 1b trial, with high dose less effective than lower doses ...

Boehringer Ingelheim has inked a research collaboration with Tessellate Bio to develop precision medicines for cancers that ...

China’s biopharmaceutical sector is showing signs of revival from its post-pandemic slump, even as its US counterpart remains ...

The FDA has asked Novavax to commit to producing post-marketing data of its Covid vaccine, the clearest example yet that the bar is higher for advancing new vaccines under HHS Secretary Robert F.